

ASX ANNOUNCEMENT

VIRTUS HEALTH LIMITED (ASX: VRT)

07 October 2014

MARCUS DARVILLE RESIGNS FROM VIRTUS' BOARD OF DIRECTORS

Sydney, Australia – Virtus Health ("Virtus", ASX: VRT) today announced that Marcus Darville has resigned from his position as a Non-Executive Director.

Mr Darville, who is a Director of private equity firm Quadrant, has served as a Director of Virtus Health since 2008. His resignation is in line with his intention to stand down from Virtus' Board of Directors once the company had reported its full year results for the financial year ending 30 June 2014; Virtus Health listed on the ASX in June 2013.

Sue Channon, CEO of Virtus Health said, "On behalf of the Board, I would like to thank Marcus for his years of contribution to Virtus Health. In particular we would like to recognise the leadership he has provided, along with the broader Quadrant team, assisting Virtus to make a successful transition to a public company which has delivered value for our shareholders, doctors and employees while continuing to improve patient outcomes."

Virtus also announce that Sonia Petering, who joined the Virtus Board in September 2014, will join the Risk Committee with immediate effect.

Contact details

Sue Channon

Chief Executive Officer
Virtus Health
+61 (0)2 9425 1722

Kyahn Williamson

Investor Relations
Buchan Consulting
+61 (0)3 9866 4722
kwilliamson@buchanwe.com.au

About Virtus

Virtus Health Limited brings together leading clinicians, scientists, researchers and support staff to provide the very best in fertility care and related services.

We have developed one of the most successful medical collaborations in the world. With more than 90 of the world's leading fertility specialists supported by 860 professional staff, we are the largest network and provider of fertility services in Australia with an international presence in Ireland. Our combined

expertise creates a unique and powerful body of knowledge which when combined with the collegial team approach of our specialists and scientists, means we are able to find new and advanced solutions for achieving success for our patients.

Our combined expertise and investment in resources and research allows us to bring clinical and scientific advances to our patients first. An example of this is the Advanced Embryo Selection technology which our group was the first to introduce to Australia.